Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for…